The US government partners with biotech giants Pfizer and BioNTech to distribute a coronavirus disease 2019 (COVID-19) vaccine; the COVID-19 death record continues to be broken; could Medicare be in financial trouble?
End-stage renal disease has long been one of the most expensive and debilitating conditions that affects Medicare beneficiaries. Not only does dialysis cost $90,000 a year—those awaiting a kidney transplant automatically qualify for Medicare—but the need to travel to a dialysis center multiple times a week disrupts employment and home life.
Among Medicare enrollees, there was substantial between-practice variation in the use of second-generation diabetes drugs between 2007 and 2015, according to a study published in JAMA Network Open. Data also revealed a concentration of use among a few prescribers and practices, who were responsible for widespread early diffusion.
The announcement of a $35 per month out-of-pocket cap for insulin for some individuals with Medicare is a real victory for the American Diabetes Association and for people with diabetes, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.